KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Accounts Payables (2016 - 2025)

Inovio Pharmaceuticals' Accounts Payables history spans 16 years, with the latest figure at $470000.0 for Q1 2025.

  • For Q1 2025, Accounts Payables changed N/A year-over-year to $470000.0; the TTM value through Mar 2025 reached $470000.0, changed N/A, while the annual FY2024 figure was $16.2 million, 18.38% down from the prior year.
  • Accounts Payables for Q1 2025 was $470000.0 at Inovio Pharmaceuticals, down from $16.2 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $74.1 million in Q3 2022 and bottomed at $470000.0 in Q1 2025.
  • The 5-year median for Accounts Payables is $26.0 million (2021), against an average of $25.7 million.
  • The largest YoY upside for Accounts Payables was 1526.28% in 2023 against a maximum downside of 99.04% in 2023.
  • A 5-year view of Accounts Payables shows it stood at $47.6 million in 2021, then crashed by 97.44% to $1.2 million in 2022, then skyrocketed by 1526.28% to $19.8 million in 2023, then decreased by 18.38% to $16.2 million in 2024, then tumbled by 97.1% to $470000.0 in 2025.
  • Per Business Quant, the three most recent readings for INO's Accounts Payables are $470000.0 (Q1 2025), $16.2 million (Q4 2024), and $19.8 million (Q4 2023).